Brokerages Set Vor Biopharma Inc. (NYSE:VOR) Target Price at $11.36

Vor Biopharma Inc. (NYSE:VOR) has earned a consensus recommendation of “Buy” from the seven research firms that are presently covering the firm, MarketBeat reports. Seven research analysts have rated the stock with a buy rating. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $11.36.

VOR has been the subject of several recent analyst reports. Wedbush restated an “outperform” rating and issued a $11.00 price target on shares of Vor Biopharma in a research note on Monday, December 9th. HC Wainwright reaffirmed a “buy” rating and issued a $17.50 target price on shares of Vor Biopharma in a report on Tuesday, December 10th. Robert W. Baird reduced their price objective on shares of Vor Biopharma from $22.00 to $14.00 and set an “outperform” rating for the company in a research note on Friday, November 8th. Finally, JMP Securities reissued a “market outperform” rating and issued a $12.00 price target on shares of Vor Biopharma in a report on Tuesday, December 10th.

Institutional Trading of Vor Biopharma

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Hsbc Holdings PLC grew its holdings in Vor Biopharma by 177.0% in the second quarter. Hsbc Holdings PLC now owns 49,038 shares of the company’s stock valued at $51,000 after purchasing an additional 31,333 shares during the period. Cubist Systematic Strategies LLC purchased a new stake in Vor Biopharma in the 2nd quarter worth $53,000. Rosalind Advisors Inc. acquired a new position in Vor Biopharma during the third quarter worth $54,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Vor Biopharma in the second quarter valued at about $63,000. Finally, Acadian Asset Management LLC increased its stake in shares of Vor Biopharma by 51.4% during the second quarter. Acadian Asset Management LLC now owns 81,305 shares of the company’s stock worth $79,000 after purchasing an additional 27,597 shares in the last quarter. 97.29% of the stock is owned by institutional investors and hedge funds.

Vor Biopharma Trading Down 2.2 %

NYSE:VOR opened at $1.33 on Friday. Vor Biopharma has a 52 week low of $0.63 and a 52 week high of $2.56. The company has a fifty day moving average of $1.04 and a 200 day moving average of $0.92.

Vor Biopharma (NYSE:VOR) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.40) earnings per share for the quarter, meeting the consensus estimate of ($0.40). On average, sell-side analysts predict that Vor Biopharma will post -1.42 EPS for the current year.

About Vor Biopharma

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.